Finally, a Drug for Bulimic Hyperphagia
New Obesity Drugs Show promise in Curbing Binge Eating
Table of Contents
Alongside established treatments for obesity, including dietary adjustments, exercise, bariatric surgery, and emerging pharmacological options, psychological support remains crucial, particularly for the notable portion of individuals grappling with eating disorders. Recent advancements in anti-obesity medications raise the question: could these drugs offer a new approach to managing bulimic hyperphagia, also known as binge eating disorder?
Approximately one-third of individuals with obesity also exhibit some form of eating disorder, with binge eating disorder being the moast prevalent, affecting roughly 20% of this population.Beyond the challenges of weight management, these individuals struggle with compulsive eating behaviors. Currently, psychologists and psychiatrists address these compulsions primarily through cognitive-behavioral therapies and support groups focused on eating disorders. Drug interventions for binge eating disorder have been limited, mainly involving the use of fluoxetine, an antidepressant.
However, the introduction of novel pharmacological treatments for obesity, including GLP-1 receptor agonists such as semaglutide, tirzepatide, and liraglutide (the latter soon to be available in France), offers a potential breakthrough. GLP-1 is a key hormone involved in regulating food intake.
These medications, while not currently reimbursed for weight loss in France, have demonstrated significant weight reduction, with patients experiencing losses of around 10% or even exceeding 20% of their body weight. Furthermore, emerging evidence suggests these drugs may also impact uncontrolled eating behaviors, including bulimic hyperphagia. Studies associated with the progress of these drugs have hinted at this effect, and Professor Sébastien Guillaume, a psychiatrist at Montpellier University Hospital specializing in obesity, notes, “Clinical experience suggests a likely impact on food compulsions in the context of obesity.” He adds that the goals of treatment include reducing the frequency and intensity of binge episodes, curbing food cravings, minimizing the psychological impact of the disorder, and promoting more flexible eating patterns.
What is Bulimic Hyperphagia?
Bulimic hyperphagia, or binge eating disorder, is characterized by recurrent episodes of consuming large quantities of food (ranging from 1,500 to 2,500 calories) in a single sitting, occurring at least once a week for a period of three months, accompanied by a sense of loss of control. Unlike bulimia nervosa, binge eating disorder does not involve compensatory behaviors such as self-induced vomiting. Individuals experiencing bulimic hyperphagia often suffer significant psychological distress, and psychotherapy remains the standard treatment approach.
GLP-1 receptor agonists, such as semaglutide (Wegovy ®), enhance the body’s response after meals by stimulating insulin production. They also slow gastric emptying and influence the brain to reduce appetite and feelings of hunger.
Evidence Suggests Calming Effect on Food Cravings
The specialized obesity center (CSO) in Poitiers conducted a study to assess the impact of semaglutide on eating habits and nutritional parameters in 58 adult patients (predominantly women, with an average age of 44.9 years) with severe obesity over a six-month period. All patients received nutritional, psychological, and medical support throughout the study.
The study findings indicated a positive effect of semaglutide on food compulsions, particularly bulimic hyperphagia. The Binge Scale (BS) score, which measures the severity of the disorder, revealed a decrease in the proportion of patients with significant bulimic hyperphagia (score > 18) from 31% to 8%, and a decrease in those with severe hyperphagia (score > 27) from 12% to 0%. After six months of treatment, no patient exhibited a severe form of bulimic hyperphagia.
Furthermore, the study observed a significant decrease in hunger scores. Analysis of 24-hour food diaries showed that patients consumed fewer calories and less protein overall.
The Importance of Nutritional Monitoring
Dr. Marie Cerdan, from the endocrinology-diabetology-nutrition service at the CHU de Poitiers, who led the study, summarized the findings: “we observed a reduction in excessive eating behaviors and a decrease in hunger scores, indicating improved appetite regulation. However, the observed decrease in protein intake highlights the need for enhanced nutritional monitoring to preserve muscle mass and maintain optimal metabolic function in individuals with obesity.”
there are indications that semaglutide may be approved for reimbursement in specific obesity cases by the end of 2025.
The World Association of Eating Disorders recently issued a statement regarding access to obesity treatments, advising authorized physicians against prescribing these medications to individuals “suffering from bulimic hyperphagia with ‘extreme overvaluation of body shape’ or with a history of anorexia nervosa or bulimia nervosa.” The association cautions that these new pharmacological treatments could potentially worsen eating disorders in these vulnerable patients.
New Obesity Drugs show Promise in Curbing Binge Eating: A Closer Look at Semaglutide
Recent advancements in obesity medications are sparking new hope for individuals struggling with binge eating disorder, also known as bulimic hyperphagia. This article explores the potential of drugs like semaglutide (wegovy®) in managing this complex condition. We’ll delve into the science, research findings, and expert perspectives to provide a comprehensive overview.
What is Binge Eating Disorder (Bulimic Hyperphagia)?
Q: What exactly is binge eating disorder, and how is it different from other eating disorders?
A: Bulimic hyperphagia (binge eating disorder) is characterized by recurrent episodes of consuming an unusually large amount of food in a discrete period of time (typically within a two-hour window), accompanied by a sense of being out of control. These episodes occur at least once a week for a duration of three months. Unlike bulimia nervosa, binge eating disorder does not involve compensatory behaviors such as self-induced vomiting, excessive exercise, or the use of laxatives.
Bulimic hyperphagia is often accompanied by meaningful psychological distress. Individuals may experience feelings of shame, guilt, and depression related to their eating behaviors.
The Role of Obesity Drugs in Managing Bulimic Hyperphagia
Q: How do novel obesity drugs, such as semaglutide, potentially help in managing binge eating disorder?
A: Drugs like semaglutide (a GLP-1 receptor agonist) work in several ways to aid in weight loss and potentially reduce binge eating. They stimulate insulin production, slow gastric emptying (making you feel fuller longer), and influence the brain to reduce appetite and feelings of hunger.These mechanisms can help reduce the frequency and intensity of binge episodes and manage food cravings.
Professor Sébastien Guillaume, a psychiatrist at Montpellier University Hospital specializing in obesity, notes, “clinical experience suggests a likely impact on food compulsions in the context of obesity.” Treatment goals encompass decreasing the frequency and intensity of the binge episodes, curbing food cravings and mitigating the psychological impact, fostering more flexible eating patterns.
Q: What is Semaglutide, and is it available right now?
A: Semaglutide is an injectable medication that is used to treat both type 2 diabetes (under the brand name Ozempic) and obesity (under the brand name Wegovy).It belongs to a class of drugs called GLP-1 receptor agonists, which mimic the effects of a naturally occurring hormone that helps regulate blood sugar and appetite. Semaglutide has been shown to reduce blood sugar levels, promote weight loss, and potentially reduce binge eating in several trials.
Study Findings: Semaglutide’s Impact on Eating habits
Q: Can you summarize the findings of the study conducted at the specialized obesity center in poitiers regarding semaglutide and bulimic hyperphagia?
A: The study conducted at the CSO in Poitiers involving 58 adult patients with severe obesity revealed encouraging results. Over a six-month period, researchers found that semaglutide had a positive impact on food compulsions, specifically bulimic hyperphagia.The Binge Scale (BS) scores, which measure the severity of the disorder, showed a significant decrease in the proportion of patients with significant bulimic hyperphagia (from 31% to 8%) and a decrease in those with severe hyperphagia (from 12% to 0%). By the end of the study, no patient exhibited the severe form of bulimic hyperphagia. Additionally, a notable decrease in hunger scores and overall calorie and protein intake was observed.
Q: What did the researchers observe about patients’ overall eating habits while taking semaglutide?
A: In the study, patients consuming fewer calories were noted coupled with a reduction in hunger scores. Analysis of the 24-hour food diaries showed that patients consumed fewer calories and less protein overall.
The Importance of Nutritional Monitoring & Treatment considerations
Q: Why is nutritional monitoring essential when using semaglutide for weight management and potentially treating bulimic hyperphagia?
A: Dr. Marie Cerdan, from the endocrinology-diabetology-nutrition service at the CHU de Poitiers, emphasized the critical need for enhanced nutritional monitoring. Though semaglutide helps decrease excessive eating behaviours and manage hunger pangs — the documented reduction in protein intake highlights the need to preserve muscle mass by carefully managing what the patients consume. Nutritional monitoring helps ensure the preservation of muscle mass and helps to support proper metabolic function in individuals with obesity.
Q: What are the concerns and advice offered by the World Association of Eating Disorders regarding these new medications?
A: The World Association of Eating Disorders cautions against prescribing these medications to individuals suffering from bulimic hyperphagia with an “extreme overvaluation of body shape” or with a history of anorexia nervosa or bulimia nervosa. The association is concerned that these pharmacological treatments could potentially worsen eating disorders in these vulnerable patients.
Q: When is semaglutide expected to be reimbursed in France?
A: There are signs that indicate semaglutide may be approved for reimbursement in select obesity cases by the end of 2025.
table Summarizing Key Study Findings
| Study Finding | Result |
|---|---|
| Reduction in Significant Bulimic Hyperphagia (BS score > 18) | Decreased from 31% to 8% of patients. |
| Reduction in Severe Hyperphagia (BS score > 27) | Decreased from 12% to 0% of patients. |
| Decrease in Hunger Scores | significant reduction observed. |
| Calorie Intake | Patients consumed fewer calories. |
| Protein Intake | Patients consumed less protein overall. |
Q: what are the key takeaways regarding semaglutide and its potential in treating binge eating disorder?
A: Semaglutide shows promise in curbing binge eating in people with obesity. This can be seen in the studies in Poitiers. If it successfully addresses the eating behaviours, reduces the psychological impact of the disorder, and promotes better habits, Semaglutide can improve the overall health of patients, and enhance their quality of life. Though, it’s critically important to remember that it is indeed still a new medication and that each patient is different and needs nutritional and mental health support.
Disclaimer: This article is intended for informational purposes only and does not constitute medical advice. Please consult your healthcare provider for any health concerns or before making any decisions related to your health or treatment.